March Altus Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

March Altus Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$2.31M	Sell	72,723 -10,000	-12%	-$339K	14.47%	2
2016 Q2	$2.69M	Buy	82,723 +61,171	+284%	+$2.05M	20.75%	1
2016 Q1	$603K	Sell	21,552 -8,249	-28%	-$180K	6.24%	8
2015 Q4	$1.06M	Sell	29,801 -19,024	-39%	-$670K	9.77%	6
2015 Q3	$1.61M	Buy	+48,825	New	+$2.03M	9.51%	3

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

March Altus Capital Management's ACAD Position: Q3 2016 in Review

March Altus Capital Management reduced its Acadia Pharmaceuticals (ACAD) stake by 12% in Q3 2016, selling an estimated $339K and leaving 72,723 shares worth $2.31M. The position accounts for 14.47% of the portfolio, ranked #2.

March Altus Capital Management first reported a position in ACAD in Q3 2015 and has held it in 5 quarters since. The position peaked at $2.69M in Q2 2016. 233 funds tracked by Wall St. Rank hold ACAD as of Q3 2016.

March Altus Capital Management held 72,723 shares of Acadia Pharmaceuticals worth $2.31M as of Q3 2016.
March Altus Capital Management sold 10,000 Acadia Pharmaceuticals shares in Q3 2016, an estimated $339K.
Acadia Pharmaceuticals made up 14.47% of March Altus Capital Management's portfolio in Q3 2016, its #2 holding.
March Altus Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2015 and has held it in 5 quarters since.
March Altus Capital Management's Acadia Pharmaceuticals position peaked at $2.69M in Q2 2016.
233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2016.

Based on March Altus Capital Management's 13F filing for Q3 2016, filed 7 Nov 2016.